beta -Lapachone (beta -Lap) triggers apoptosis in a number of human breast
and prostate cancer cell lines through a unique apoptotic pathway that is d
ependent upon NQO1, a two-electron reductase. Downstream signaling pathway(
s) that initiate apoptosis following treatment with beta -Lap have not been
elucidated, Since calpain activation was suspected in beta -Lap-mediated a
poptosis, we examined alterations in Ca2+ homeostasis using NQO1-expressing
MCF-7 cells. beta -Lap-exposed MCF-7 cells exhibited an early increase in
intracellular cytosolic Ca2+, from endoplasmic reticulum Ca2+ stores, compa
rable to thapsigargin exposures. 1,2-Bis-(2-aminophenoxy) ethane-N,N,N ' ,N
' -tetraacetic acid-acetoxymethyl ester, an intracellular Ca2+ chelator, b
locked early increases in Ca2+ levels and inhibited beta -Lap-mediated mito
chondrial membrane depolarization, intracellular ATP depletion, specific an
d unique substrate proteolysis, and apoptosis, The extracellular Ca2+ chela
tor, EGTA, inhibited later apoptotic end points (observed >8 h, e.g. substr
ate proteolysis and DNA fragmentation), suggesting that later execution eve
nts were triggered by Ca2+ influxes from the extracellular milieu. Collecti
vely, these data suggest a critical, but not sole, role for Ca2+ in the NQO
1-dependent cell death pathway initiated by beta -Lap. Use of beta -Lap to
trigger an apparently novel, calpain like-mediated apoptotic cell death cou
ld be useful for breast and prostate cancer therapy.